


 Cite this: *Chem. Commun.*, 2020, 56, 6989

 Received 13th January 2020,  
Accepted 12th May 2020

DOI: 10.1039/d0cc00329h

rsc.li/chemcomm

# Silica-coated phosphorescent nanoprobes for selective cell targeting and dynamic bioimaging of pathogen–host cell interactions†

 Federico Iovino,<sup>ab</sup> Padryk Merkl,<sup>a</sup> Anastasia Spyrogianni,<sup>‡</sup>  
Birgitta Henriques-Normark<sup>ab</sup> and Georgios A. Sotiriou<sup>id</sup>\*<sup>a</sup>

**Fluorescence *in vitro* bioimaging suffers from photobleaching of organic dyes, thus, functional probes with superior photostability are urgently needed. Here, we address this challenge by developing novel silica-coated nanophosphors that may serve as superior luminescent nanoprobes compatible with conventional fluorescence microscopes. We specifically explore their suitability for dynamic *in vitro* bioimaging of interactions between bacterial pathogens and host cells, and further demonstrate the facile surface functionalization of the amorphous silica layer with antibodies for selective cell targeting.**

Optical fluorescence microscopy is one of the most commonly employed tools when studying nanoparticle–cell interactions *in vitro*. In these studies nanoparticles are often labelled with an organic fluorophore (dye) that upon excitation at a specific wavelength emits light at a different wavelength, that is subsequently detected using the appropriate excitation and emission filters. A plethora of commercially-available organic dyes exist that offer a bright signal and are traditionally used for labelling biomolecules (*e.g.* proteins, peptides). However, a major drawback of organic dyes for bioimaging is their poor photostability.<sup>1</sup> Even though useful images of nanoparticle–cell interactions may be obtained with these dyes at one time-point, it is not possible to perform dynamic imaging over time because such organic fluorophores rapidly degrade during continuous irradiation, thus losing their intensity and exhibiting the so-called photobleaching.<sup>2,3</sup> Dynamic bioimaging enables tracking of interactions in real-time, obtaining not only spatial but also

temporal information of specific important events during an experiment, crucial in several fields including host–pathogen interaction studies.

One novel class of nanoparticles inherently luminescent and characterized by superior optical stability are nanophosphors.<sup>4–6</sup> Nanophosphors are nanoparticles that typically consist of a crystal host matrix that is doped with rare earth ions and are routinely used in lighting.<sup>7</sup> The excitation and emission of nanophosphors depends on both the crystalline material as well as the selection of the rare earth ions and in fact, by co-doping such nanoparticles with multiple rare earth ions it is possible to obtain color tunability.<sup>8</sup> These materials may exhibit superior performance in biosensing *in vitro*,<sup>9,10</sup> however, one major limitation of such nanophosphors lies at their excitation wavelength. The excitation spectra of most nanophosphors have strong and broad charge transfer (CT) bands in the UV-C ( $\lambda = 100–280$  nm) and UV-B ( $\lambda = 280–315$  nm) regions,<sup>11</sup> in which, however, the standard optical components of conventional fluorescence microscopes strongly absorb and the shortest wavelength in which they operate is in the near UV region at  $\lambda = 315–400$  nm (UV-A). These technical issues inhibit *in vitro* imaging with nanophosphors and conventional microscopes requiring complex and expensive solutions (*e.g.* quartz optical components or lasers as excitation).<sup>12,13</sup>

One strategy to tune the excitation bands of nanophosphors to UV-A is by co-doping  $\text{YVO}_4:\text{Eu}^{3+}$  nanoparticles with  $\text{Bi}^{3+}$  ions.<sup>14–17</sup> The  $\text{Bi}^{3+}$  doping shifts the excitation spectrum of  $\text{YVO}_4:\text{Eu}^{3+}$  nanophosphors to near-UV spectral region rendering these nanoparticles suitable nanoprobes for *in vitro* bioimaging with conventional fluorescence microscopes<sup>18</sup> and even exhibit attractive properties as imaging nanoprobes for correlative cathodoluminescence electron microscopy.<sup>19</sup>

Here, we develop novel bioimaging nanoprobes based on  $\text{YVO}_4:\text{Eu}^{3+},\text{Bi}^{3+}$  nanoparticles and further advance the state-of-the-art by *in situ* coating them during their gas-phase synthesis in a single step with a nanothin ( $\sim 3$  nm) layer of amorphous silica ( $\text{SiO}_2$ ).<sup>20,21</sup> We explore the optical stability of these nanoprobes and directly compare them with an organic dye by

<sup>a</sup> Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, SE-17165 Stockholm, Sweden. E-mail: georgios.sotiriou@ki.se

<sup>b</sup> Department of Clinical Microbiology, Karolinska University Hospital, SE-17176 Stockholm, Sweden

<sup>c</sup> Particle Technology Laboratory, Institute of Process Engineering, Department of Mechanical and Process Engineering, ETH Zurich, CH-8092 Zurich, Switzerland

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d0cc00329h

\* Current address: Drug Formulation and Delivery, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, CH-8093 Zurich, Switzerland.




performing *in vitro* dynamic bioimaging of lung epithelial cells challenged with the bacterium *Streptococcus pneumoniae*. We demonstrate the facile biofunctionalization of these nanoprobes with antiCK8 antibody that readily binds to the type II cytoskeletal 8 keratin protein expressed in these lung epithelial cells.<sup>22</sup> We perform cell experiments with conventional upright cell culture orientation (cells are placed on the bottom of wells), but also with inverted cell culture orientation<sup>23</sup> in which the cells are placed on top of the well. Monitoring the luminescence from nanoprobes enables direct quantitative comparison of the targeting capacity of antiCK8-functionalized nanoprobes with non-functionalized ones, and functionalized with, bovine serum albumin (BSA).

An important characteristic of luminescent nanoprobes is to have a biocompatible surface that may be easily functionalized with biomolecules. One of the most understood such surface for bioconjugation is amorphous SiO<sub>2</sub>. The enclosed flame aerosol reactor employed in this study allows for the single-step production of core-shell nanoparticles that are encapsulated by a nanothin layer of SiO<sub>2</sub> (Fig. 1a). In fact this scalable and reproducible process<sup>24</sup> has been successfully employed to encapsulate a variety of materials such as TiO<sub>2</sub>,<sup>20</sup> Fe<sub>2</sub>O<sub>3</sub>,<sup>25</sup> Ag,<sup>26</sup> Au,<sup>27</sup> Y<sub>2</sub>O<sub>3</sub>:Tb<sup>3+</sup>,<sup>28</sup> to name a few. Fig. 1b and c shows high resolution transmission electron microscope images of the SiO<sub>2</sub>-coated YVO<sub>4</sub>:Eu<sup>3+</sup>,Bi<sup>3+</sup> (23 wt% SiO<sub>2</sub>) nanoparticles produced here in which the darker crystalline core is encapsulated by a smooth, nanothin (~3 nm) amorphous SiO<sub>2</sub> coating. The presence of SiO<sub>2</sub> as a coating is further validated in Fig. 1d and e that shows high-angle annular dark field (HAADF) electron microscopy images and the corresponding elemental mapping (obtained by energy-dispersive X-ray spectroscopy-EDX, further images shown in ESI,† Fig. S1a) in which the core material (red dots, monitoring V) is easily distinguished from the shell (green dots, monitoring Si).

The elemental composition is further validated by the EDX spectra of selected areas in these images (ESI,† Fig. S1b).

The crystallinity of the core material is confirmed by X-ray powder diffraction (XRD) (ESI,† Fig. S2) that reveals the characteristic tetragonal YVO<sub>4</sub> crystal phase with an average crystal diameter  $d_{\text{XRD}} = 26$  nm (calculated from the main diffraction peak at 24.9°). No Eu-oxide nor Bi-oxide peaks (with a minor Y<sub>2</sub>O<sub>3</sub> phase of 3 wt% calculated by Rietveld refinement) are detected in the XRD pattern further indicating incorporation of both the Eu<sup>3+</sup> and Bi<sup>3+</sup> ions in the crystal host lattice.<sup>18</sup> The incorporation of both Eu<sup>3+</sup> and Bi<sup>3+</sup> ions renders these nanoparticles luminescent by near-UV excitation with emission in the red part of the spectrum as shown in Fig. 1f, and these excitation and emission profiles allow them to be utilized with traditional fluorescence microscopes for live cell imaging studies with existing filter sets (*e.g.* excitation 350 ± 50 nm (DAPI) and emission 620 ± 26 nm (TRITC)).<sup>18</sup>

The presence of the amorphous SiO<sub>2</sub> surface is further validated by the attenuated total reflection Fourier transform infrared spectra (FTIR-ATR) of the nanoprobes. Fig. 1g shows such FTIR-ATR spectra in which the Si–O–Si and surface –OH bands and/or absorbed water around 1000 cm<sup>-1</sup> and 3200 cm<sup>-1</sup> are seen respectively.<sup>29</sup> The hydrophilic amorphous SiO<sub>2</sub> coating facilitates apart from nanoparticle dispersion in aqueous solutions (ESI,† Fig. S3),<sup>21</sup> also biomolecule functionalization by physical adsorption, an increasingly popular route for decorating the surface of nanoparticles with targeting antibodies.<sup>30,31</sup> Upon incubation of these nanoprobes with bovine serum albumin (BSA, mass ratio is 1 : 1) in phosphate buffered saline (PBS) at room temperature for 30 min followed by washing, the characteristic amide I and II bands from BSA<sup>32</sup> appear around 1600 cm<sup>-1</sup> indicating its presence on the




**Fig. 1** (a) Schematic of the enclosed flame spray pyrolysis reactor for the production of the SiO<sub>2</sub>-coated YVO<sub>4</sub>:Eu<sup>3+</sup>,Bi<sup>3+</sup> nanoparticles by swirl injection of the Si-precursor vapor downstream after formation of core nanoparticles. (b and c) Transmission electron microscopy images of the SiO<sub>2</sub>-coated YVO<sub>4</sub>:Eu<sup>3+</sup>,Bi<sup>3+</sup> nanoparticles in which the characteristic amorphous nanothin SiO<sub>2</sub> layer encapsulates the core phosphor nanoparticles. (d) High-angle annular dark field from a scanning tunneling electron microscopy image and the corresponding elemental mapping (e) highlighting the V (core) and Si (shell) elements. (f) The excitation (blue line, monitoring emission at  $\lambda = 616$  nm) and emission (red line, excitation at  $\lambda = 276$  nm) spectra of the nanophosphors. (g) FTIR-ATR spectra of nanoprobes before (red line) and after (blue line) their functionalization with bovine serum albumin (BSA).



surface of the nanoprobe and furthermore an increase in the intensity in the region of the amide A band around  $3300\text{ cm}^{-1}$  (inset in Fig. 1g), even though this band could also be attributed to the presence of water. The biofunctionalization is further validated here by the changes in the hydrodynamic diameter of the nanoprobe after the protein biofunctionalization as well as by the bicinchoninic acid (Pierce BCA) assay (ESI,† Table S1). The protein biofunctionalization does not affect the excitation and emission profile of the nanoprobe (ESI,† Fig. S4).

The suitability of the developed nanoprobe for dynamic bioimaging is evaluated by challenging human lung epithelial cells (A549) with *S. pneumoniae* bacteria that express the green fluorescent protein GFP. *S. pneumoniae* is a main cause of pneumonia, sepsis and meningitis, and one of the most common causes of deaths worldwide.<sup>33,34</sup> To cause disease, pneumococci interact with human cell barriers such as the alveolar epithelium in pneumonia<sup>35</sup> or the blood–brain barrier in meningitis.<sup>34</sup> Thus, it is important to monitor its interactions with host cells over time. To visualize the cell barrier, host cells have been pre-labelled either with phalloidin that is an organic dye that binds to the cytoskeleton, or with the developed luminescent nanoprobe (1 h incubation prior addition of bacteria at  $C = 30\text{ mg L}^{-1}$ ). The as-prepared nanoparticles do not exhibit any cytotoxicity for up to  $100\text{ mg L}^{-1}$  (ESI,† Fig. S5) justifying the imaging dose. Bacteria–host cell interactions are then monitored continuously for 30 min, utilizing constant imaging conditions (exposure time and light intensity) as shown in Fig. 2a. Even though the cytoskeleton staining by the organic dye provides a bright image for time  $t = 0\text{ min}$ , the signal gradually degrades over time, exhibiting photobleaching, and the cells cannot be detected after 30 min. In contrast, the signal of cells stained with nanoprobe does not degrade during the time studied here highlighting their superior photostability, but also rendering it possible for the first time to visualize in real-time and *in situ* pathogen–host cell interactions (ESI,† Fig. S6 for further images). Fig. 2b shows red signal from such images, quantitatively validating that the nanoprobe exhibit superior stability over a commonly used organic dye that loses more than 3 times its intensity over the first 5 min of imaging. The performance of the nanoprobe during *in vitro* bioimaging is not significantly affected by the primary particle




**Fig. 2** (a) A549 lung cancer epithelial cells with conventional phalloidin staining (top row,  $C = 2\text{ units per mL}$ ) and with the red nanoprobe (bottom row,  $C = 30\text{ mg L}^{-1}$ ), co-incubated with *S. pneumoniae* expressing GFP (green) over different time points (0, 10, 30 min). Images have same scale bar. (b) Quantitative analysis of the luminescence intensity signal originating from the red fluorescence emission filter for both these cell cultures stained with the nanoprobe (NP) and phalloidin.  $N \geq 2$ .

size uniformity given the rather homogeneous signal from the cell membrane upon its labeling with the nanoprobe.

Furthermore, the functionality of the developed nanoprobe here is evaluated by selectively targeting the cytoskeleton of lung epithelial cells utilizing nanoprobe functionalized with antiCK8 antibody. The cells are incubated for 1 h at  $37\text{ }^\circ\text{C}$  with three formulations ( $C = 50\text{ mg L}^{-1}$ , see ESI,† Fig. S7 for  $100\text{ mg L}^{-1}$ ): (i) pure, non-functionalized nanoprobe (NPs only), (ii) antiCK8 functionalized nanoprobe (antiCK8-NPs) and (iii) nanoprobe functionalized with BSA (BSA-NPs) that was used as a negative control due to the high biocompatibility and minimal interaction of albumin with host cells.<sup>36</sup> Afterwards, the cultures are washed and placed in the fluorescence microscope, and the nanoprobe luminescence is monitored to study their interaction with the host cells. Fig. 3a shows representative transmission-DIC, red luminescence and the merged microscope images from these conditions for two different cell culture orientations: (i) upright and (ii) inverted.

The quantified signal intensity from these images is shown in Fig. 3b. Upon the traditional upright cell culture orientation (the cells grow on the bottom of the wells), there is a strong nanoprobe signal from both the NPs only and the antiCK8-NPs. Pure, non-functionalized nanoprobe readily interact with the cells due to particle sedimentation and other non-specific pathways;<sup>23,37</sup> however, when the nanoprobe are functionalized with the targeting antiCK8 antibody, their cell-associated amount is drastically increased ( $\sim 2$ -fold). The nanoprobe seem to be internalized by the cells as signals are detected continuously from the apical to the basolateral side (ESI,† Fig. S8). When the BSA-NPs are employed, there is almost no



**Fig. 3** (a) Microscopy images of A549 cells incubated with  $50\text{ mg L}^{-1}$  of (i) pure nanoprobe, (ii) biofunctionalized with antiCK8, and (iii) biofunctionalized with BSA at upright (cells bottom of well) and inverted cell culture orientation (cells on top) displaying the DIC (left column), red fluorescence (middle column) and merge images (right column). Scale bar is  $25\text{ }\mu\text{m}$ . (b) Quantitative analysis of the nanoprobe uptake from these images monitoring the red fluorescence,  $N = 3$ . (c) Western blots from A549 cell lysates incubated with (i) pure antiCK8 antibody, (ii) nanoprobe, (iii) nanoprobe biofunctionalized with antiCK8, and (iv) biofunctionalized with BSA.



signal, indicating that the BSA functionalization on the nanoprobe effectively inhibits any interaction between the nanoprobe and the cells.<sup>38</sup>

To further study the targeting capacity of the antibody-functionalized nanoprobe, an inverted cell culture orientation is employed in which the cells grow on top of the wells (see scheme in Fig. 3). This way, any interaction between cells and nanoprobe due to particle sedimentation is avoided and only interactions by Brownian diffusion are taken into account.<sup>23,37,39</sup>

Indeed, the signal intensity of non-functionalized nanoprobe (NPs only) in inverted orientation is >4 times decreased when compared to that of upright orientation indicating their reduced interaction with the cells. Most importantly, the interaction of antiCK8-NPs in the inverted cell orientation is further enhanced by almost 3-fold than the uncoated ones indicating the targeting capacity/affinity of the antibody-functionalized nanoprobe towards the cells. Similar to the upright cell orientation, the BSA-NPs exhibit minimal interaction with the cells. Finally, to further validate that the antiCK8 antibody is indeed delivered to the cells when functionalized on the nanoprobe, we measure the western blots of the cell lysates upon incubation of the three different nanoprobe formulations along with the pure antibody. Fig. 3c shows these western blots in which the presence of the antiCK8 antibody is detected only when cells are incubated either with the pure antibody or with the antibody-functionalized nanoprobe.

In summary, we develop a novel silica coated nanoprobe suitable for *in vitro* dynamic bioimaging with conventional fluorescence microscopes. These nanoprobe exhibit superior optical photostability, rendering it possible to monitor pathogen–host cell interactions over time without the loss of any imaging signal. The biocompatible amorphous silica coating facilitates the surface biofunctionalization of these nanoprobe, and the targeting of biomolecules is demonstrated by selectively targeting lung epithelial cells with antiCK8 functionalized nanoprobe in both upright and inverted cell culture orientations. These novel luminescent nanoprobe could help elucidating mechanisms for how bacterial pathogens interact with host cells, and constitute a valuable tool in nanomedicine research.

## Conflicts of interest

There are no conflicts to declare.

## References

- J. C. G. Bunzli, *J. Lumin.*, 2016, **170**, 866–878.
- M. Montalti, A. Cantelli and G. Battistelli, *Chem. Soc. Rev.*, 2015, **44**, 4853–4921.
- S. Veerananarayanan, A. C. Poulouse, S. Mohamed, A. Aravind, Y. Nagaoka, Y. Yoshida, T. Maekawa and D. S. Kumar, *J. Fluoresc.*, 2012, **22**, 537–548.
- G. F. Wang, Q. Peng and Y. D. Li, *Acc. Chem. Res.*, 2011, **44**, 322–332.
- O. S. Wolfbeis, *Chem. Soc. Rev.*, 2015, **44**, 4743–4768.
- A. Escudero, C. Carrillo-Carrion, M. V. Zyuzin and W. J. Parak, *Top. Curr. Chem.*, 2016, **374**, 48.
- X. Y. Liu, Y. Li, C. K. Tsung and J. Li, *Chem. Commun.*, 2019, **55**, 10669–10672.
- G. A. Sotiriou, M. Schneider and S. E. Pratsinis, *J. Phys. Chem. C*, 2011, **115**, 1084–1089.
- D. F. Henning, P. Merkl, C. H. Yun, F. Iovino, L. Xie, E. Mouzourakis, C. Moularas, Y. Deligiannakis, B. Henriques-Normark, K. Leifer and G. A. Sotiriou, *Biosens. Bioelectron.*, 2019, **132**, 286–293.
- A. Pratsinis, G. A. Kelesidis, S. Zuercher, F. Krumeich, S. Bolisetty, R. Mezzenga, J. C. Leroux and G. A. Sotiriou, *ACS Nano*, 2017, **11**, 12210–12218.
- G. Blasse, *J. Chem. Phys.*, 1966, **45**, 2356–2360.
- J. Pan, D. Wan, Y. Bian, H. Sun, C. Zhang, F. Jin, Z. Huang and J. Gong, *AIChE J.*, 2013, **59**, 4494–4501.
- G. A. Sotiriou, D. Franco, D. Poulidakos and A. Ferrari, *ACS Nano*, 2012, **6**, 3888–3897.
- T. Ohno, Y. Iso and T. Isobe, *ECS J. Solid State Sci. Technol.*, 2016, **5**, R142–R145.
- W. J. Park, M. K. Jung and D. H. Yoon, *Sens. Actuators, B*, 2007, **126**, 324–327.
- A. Escudero, C. Carrillo-Carrion, M. V. Zyuzin, S. Ashraf, R. Hartmann, N. O. Nunez, M. Ocana and W. J. Parak, *Nanoscale*, 2016, **8**, 12221–12236.
- Y. C. Chen, S. C. Huang, Y. K. Wang, Y. T. Liu, T. K. Wu and T. M. Chen, *Chem. – Asian J.*, 2013, **8**, 2652–2659.
- A. Spyrogianni, P. Tiefenboeck, F. H. L. Starsich, K. Keevend, F. Krumeich, I. K. Herrmann, J. C. Leroux and G. A. Sotiriou, *AIChE J.*, 2018, **64**, 2947–2957.
- K. Keevend, L. Puust, K. Kurvits, L. R. H. Gerken, F. H. L. Starsich, J. H. Li, M. T. Matter, A. Spyrogianni, G. A. Sotiriou, M. Stiefel and I. K. Herrmann, *Nano Lett.*, 2019, **19**, 6013–6018.
- A. Teleki, M. C. Heine, F. Krumeich, M. K. Akhtar and S. E. Pratsinis, *Langmuir*, 2008, **24**, 12553–12558.
- G. A. Sotiriou, A. M. Hirt, P. Y. Lozach, A. Teleki, F. Krumeich and S. E. Pratsinis, *Chem. Mater.*, 2011, **23**, 1985–1992.
- F. Iovino, D. L. Hammarlof, G. Garriss, S. Brovall, P. Nannapaneni and B. Henriques-Normark, *J. Clin. Invest.*, 2016, **126**, 2821–2826.
- A. Spyrogianni, I. K. Herrmann, M. S. Lucas, J.-C. Leroux and G. A. Sotiriou, *Nanomedicine*, 2016, **11**, 2483–2496.
- S. E. Pratsinis, *AIChE J.*, 2010, **56**, 3028–3035.
- A. Teleki, M. Suter, P. R. Kidambi, O. Ergeneman, F. Krumeich, B. J. Nelson and S. E. Pratsinis, *Chem. Mater.*, 2009, **21**, 2094–2100.
- G. A. Sotiriou, T. Sannomiya, A. Teleki, F. Krumeich, J. Vörös and S. E. Pratsinis, *Adv. Funct. Mater.*, 2010, **20**, 4250–4257.
- G. A. Sotiriou, F. Starsich, A. Dasargyri, M. C. Wurnig, F. Krumeich, A. Boss, J.-C. Leroux and S. E. Pratsinis, *Adv. Funct. Mater.*, 2014, **24**, 2818–2827.
- G. A. Sotiriou, M. Schneider and S. E. Pratsinis, *J. Phys. Chem. C*, 2012, **116**, 4493–4499.
- A. Teleki, M. K. Akhtar and S. E. Pratsinis, *J. Mater. Chem.*, 2008, **18**, 3547–3555.
- R. Cagliani, F. Gatto and G. Bardi, *Materials*, 2019, **12**, 1991.
- M. Tonigold, J. Simon, D. Estupinan, M. Kokkinopoulou, J. Reinholz, U. Kintzel, A. Kaltbeitzel, P. Renz, M. P. Domogalla, K. Steinbrink, I. Lieberwirth, D. Crespy, K. Landfester and V. Mailander, *Nat. Nanotechnol.*, 2018, **13**, 862–869.
- J. Grdadolink and Y. Marechal, *Biopolymers*, 2001, **62**, 40–53.
- B. Henriques-Normark and E. I. Tuomanen, *Cold Spring Harbor Perspect. Med.*, 2013, **3**, a010215.
- F. Iovino, J. Seinen, B. Henriques-Normark and J. M. van Diji, *Trends Microbiol.*, 2016, **24**, 307–315.
- P. Shivshankar, C. Sanchez, L. F. Rose and C. J. Orihuela, *Mol. Microbiol.*, 2009, **73**, 663–679.
- F. F. An and X. H. Zhang, *Theranostics*, 2017, **7**, 3667–3689.
- A. Spyrogianni, G. A. Sotiriou, D. Brambilla, J.-C. Leroux and S. E. Pratsinis, *J. Aerosol Sci.*, 2017, **108**, 56–66.
- J. Mariam, S. Sivakami and P. M. Dongre, *Drug Delivery*, 2016, **23**, 2668–2676.
- N. Feliu, X. Sun, R. A. A. Puebla and W. J. Parak, *Langmuir*, 2017, **33**, 6639–6646.

